Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Also overlooked and Positive was this

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Nov 15, 2021 2:37pm

143 Views

Post# 34128445

RE:Also overlooked and Positive was this

The Mexican isotretinoin market is a steadily growing market and is expected to show continued growth in the coming years.

The value of the Mexican isotretinoin market was approximately US$20 million US in 2017 and has grown at a compounded rate of 16% in the past five years1.

This would increase to about $40 million today and that should increase as sales promotions begin..

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario